Website | cmcapital.com |
Phone | +61 7 3838 2800 |
cmcideals@cmcapit... | |
Employees | |
Description | capital fund |
CM Capital invests in companies that offer differentiated products with high barriers to entry and substantial market opportunities. We also value talented management teams who have the skill, drive and enthusiasm to take their companies to a market leadership position.
Company | Date | Round | Size | Participants |
ThreatMetrix ^{} | 3/2014 | Series E | $20M | 6 |
Datacastle ^{} | 12/2012 | Venture Round | $3M | 1 |
Pathway Therapeutics ^{} | 5/2011 | Series A | $7.5M | 2 |
Mantara ^{} | 5/2011 | Venture Round | $7M | 3 |
Datacastle ^{} | 2/2011 | Venture Round | $2M | 1 |
ThreatMetrix ^{} | 10/2010 | Series C | $12.1M | 4 |
Pathway Therapeutics ^{} | 8/2010 | Series A | $4.5M | 3 |
Datacastle ^{} | 11/2009 | Venture Round | $3M | 1 |
Dilithium Networks ^{} | 10/2009 | Venture Round | $10.9M | 6 |
Pathway Therapeutics ^{} | 10/2009 | Series A | $2.4M | 2 |
ThreatMetrix ^{} | 10/2009 | Series B | $6.1M | 2 |
Mantara ^{} | 5/2009 | Series C | $7.6M | 4 |
Piedmont Pharmaceuticals ^{} | 4/2009 | Venture Round | $5M | 1 |
Datacastle ^{} | 11/2008 | Series A | $5.3M | 1 |
Xumii ^{} | 9/2008 | Venture Round | $5.5M | 2 |
Mantara ^{} | 7/2008 | Venture Round | $5.8M | 4 |
Pathway Therapeutics ^{} | 6/2008 | Series A | $9.6M | 2 |
AdGent Digital ^{} | 3/2008 | Series A | $5.3M | 1 |
Xumii ^{} | 11/2007 | Venture Round | $4.3M | 2 |
Mantara ^{} | 9/2007 | Series B | $12.8M | 4 |
Dilithium Networks ^{} | 11/2006 | Series D | $16.8M | 5 |
bCODE Pty Ltd in liquidation ^{} | 10/2005 | Series A | $3.79M | 2 |
Dilithium Networks ^{} | 3/2005 | Series C | $18M | 6 |
Dilithium Networks ^{} | 4/2003 | Series B | $10M | 5 |